Nature communications · 2025
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
СтатьяКлиническое исследование III фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanaka Kentaro, Sugisaka Jun, Shiraishi Yoshimasa, Watanabe Yasutaka, Daga Haruko, Azuma Koichi, Nishino Kazumi, Mori Masahide, Ota Takayo, Saito Haruhiro, Hata Akito, Sakaguchi Tadashi, Kozuki Toshiyuki, Akamatsu Hiroaki, Matsumoto Hirotaka, Tachihara Motoko, Wakuda Kazushige, Sato Yuki, Ozaki Tomohiro, Tsuchiya-Kawano Yuko, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Okamoto Isamu
Аннотация
Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.